ArticlePharmaceutics2018
Designing of the Anticancer Nanocomposite with Sustained Release Properties by Using Graphene Oxide Nanocarrier with Phenethyl Isothiocyanate as Anticancer Agent.
Article in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Isothiocyanates in Cancer Therapeutics - A Molecular Perspective.Chemistry & biodiversity · 2026Review
- Tailoring CdO-CuO-ZnO Mixed Metal Oxide Nanocomposites for Anticancer Activity via Co-Precipitation Method.Nanotechnology, science and applications · 2025Article
- Novel Graphene Oxide/Quercetin and Graphene Oxide/Juglone Nanostructured Platforms as Effective Drug Delivery Systems with Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2022Article
- Assessment of Methodological Pipelines for the Determination of Isothiocyanates Derived from Natural Sources.Antioxidants (Basel, Switzerland) · 2022Review
- Effects of Metallic and Carbon-Based Nanomaterials on Human Pancreatic Cancer Cell Lines AsPC-1 and BxPC-3.International journal of molecular sciences · 2021Article
- Role of solution chemistry in the attachment of graphene oxide nanoparticles onto iron oxide minerals with different characteristics.Environmental science and pollution research international · 2021Article
- Phenethyl Isothiocyanate-Containing Carbomer Gel for Use against Squamous Cell Carcinoma.Pharmaceutics · 2021Article
- A porous reduced graphene oxide/chitosan-based nanocarrier as a delivery system of doxorubicin.RSC advances · 2019Article
- Chlorogenic Acid Entrapped in Hybrid Materials with High PEG Content: A Strategy to Obtain Antioxidant Functionalized Biomaterials?Materials (Basel, Switzerland) · 2019Article
- Graphene Oxide⁻PEG⁻Protocatechuic Acid Nanocomposite Formulation with Improved Anticancer Properties.Nanomaterials (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study anticancer nanocomposite was designed using graphene oxide (GO) as nanocarrier and Phenethyl isothiocyanate (PEITC) as anticancer agent. The designed formulation was characterized in detailed with XRD, Raman, UV/Vis, FTIR, DLS and TEM etc. The designed anticancer nanocomposite showed much better anticancer activity against liver cancer HepG2 cells compared to the free drug PEITC and was also found to be nontoxic to the normal 3T3 cells. In vitro release of the drug from the anticancer nanocomposite formulation was found to be sustained in human body simulated phosphate buffer saline (PBS) solution of pH 7.4 (blood pH) and pH 4.8 (intracellular lysosomal pH). This study suggests that GO could be developed as an efficient drug carrier to conjugate with PEITC for pharmaceutical applications in cancer chemotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.